Related Experiment Video

Updated: Jul 12, 2026

Identification of Key Factors Regulating Self-renewal and Differentiation in EML Hematopoietic Precursor Cells by RNA-sequencing Analysis
12:44

Identification of Key Factors Regulating Self-renewal and Differentiation in EML Hematopoietic Precursor Cells by RNA-sequencing Analysis

Published on: November 11, 2014

New insights into RSK activation and hematopoietic cancer

Ana Cuadrado1, Angel R Nebreda

  • 1CNIO (Spanish National Cancer Center), Melchor Fernández Almagro, 3, E-28029 Madrid, Spain.

Cancer Cell
|September 6, 2007
PubMed

Insights

Fibroblast growth factor receptor 3 (FGFR3) directly phosphorylates RSK2, a key enzyme in multiple myeloma (MM) cell survival. This discovery highlights a new therapeutic target for treating FGFR3-driven hematopoietic malignancies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The receptor tyrosine kinase FGFR3 is implicated in various hematopoietic malignancies.
  • Multiple myeloma (MM) is a cancer of plasma cells, often associated with genetic abnormalities like the t(4;14) translocation.

Discussion:

  • This study identifies RSK2 as a direct substrate of FGFR3 in t(4;14)-positive MM cells.
  • FGFR3 phosphorylates RSK2 at Tyr529, priming it for activation by ERK1/2 kinases.
  • Activated RSK2 is crucial for the survival of MM cells expressing FGFR3.

Key Insights:

  • FGFR3 directly activates RSK2 through phosphorylation, establishing a novel signaling pathway in MM.
  • RSK2 activation is essential for the proliferation and survival of FGFR3-dependent MM cells.
  • This finding offers a potential therapeutic strategy targeting the FGFR3-RSK2 axis in multiple myeloma.

Outlook:

  • Further research into the FGFR3-RSK2 pathway could reveal new therapeutic targets for multiple myeloma.
  • Investigating the role of RSK2 in other FGFR3-associated cancers may broaden treatment possibilities.
  • Developing specific inhibitors of RSK2 or its upstream activators could offer novel treatment options for MM patients.

More Related Videos

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models08:14

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Published on: October 3, 2019

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Hematopoiesis01:21

Hematopoiesis

The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...